SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

BABA is facing downward pressure amid reports of internal security bans regarding foreign AI coding tools and ongoing legal headwinds, leading to intense community debate between those viewing it as a distressed value opportunity and others calling it a permanent value trap. The stock remains highly volatile as traders focus on its oversold RSI levels and institutional rebalancing, with many investors debating whether its current technical weakness marks a bottom or a continued downtrend.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

The KORU ETF is experiencing extreme volatility as investors react to aggressive selling from South Korea's National Pension Service and broader uncertainty surrounding leveraged semiconductor positions. The community is focused on the high-stakes interplay between memory chip supply-demand dynamics, upcoming corporate events like stock splits and IPOs, and the significant risks inherent in highly leveraged 3x exposure.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a significant surge in momentum as the market focuses on its role in providing essential power infrastructure for the rapidly growing AI data center sector. Investors are actively debating the company's recent capital raise through a public offering, balancing concerns over shareholder dilution against the potential for long-term growth driven by increased manufacturing capacity and large-scale project demand.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is experiencing extreme volatility as investors weigh the potential dilution from a new large-scale share resale filing against the company's massive government funding and strategic expansion. While community sentiment remains split between long-term confidence in its domestic supply chain dominance and frustration over recent sharp price declines, traders are actively debating whether current support levels offer a buy-the-dip opportunity or if further downside is likely.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing significant market interest driven by rumors of a potential buyout and excitement over the company's strategic pivot to cut costs by closing internal research facilities. Investors are actively discussing the stock's high short interest and its potential as a prime acquisition target, leading to increased volume and bullish sentiment surrounding its core commercial products.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense volatility and speculative fervor as investors debate its role in the broader crypto infrastructure sector and its controversial ties to the Trump family. The community remains deeply divided, with some traders citing accumulation patterns and a potential bull run in Bitcoin as catalysts, while others actively warn of a recurring cycle of reverse stock splits and share dilution.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is seeing intense community focus following the FDA's grant of Fast Track designation for its lead Hepatitis B treatment, imdusiran, alongside ongoing anticipation of a major settlement with Pfizer. While retail investors remain frustrated by the stock's lack of sustained upward momentum, recent filings reveal significant institutional accumulation and continued high short interest, fueling active discussions regarding potential buyout scenarios and the company's long-term patent litigation value.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is currently trending due to its recent acquisition by Vertex Pharmaceuticals in a multibillion-dollar all-cash deal, which has triggered massive gains and significant merger arbitrage interest. The community is actively discussing the substantial premium paid for the company's rare endocrine pipeline and how this acquisition validates the broader endocrine and obesity biotech landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing significant upward momentum as investors speculate on potential buyout interest and anticipate upcoming clinical data from the maintenance study of its obesity drug, VK2735. The stock is currently a major talking point in the healthcare sector, with the community actively discussing institutional accumulation, potential short-squeeze dynamics, and the broader competitive landscape for next-generation weight-loss medications.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing intense market volatility as investors weigh the company's unexpected 75-million-share public offering against its positive revenue guidance. While the community is sharply divided, discussions center on whether the dilution is a necessary step to secure federal manufacturing loans or a management misstep that erodes shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABR or none of that happens and the NPLs grow in Q2/3/4 and the equity gets wiped out... 

Management has been saying they have &quot;clear path to resolution&quot; for 8 quarters have barely made a dent in the NPL balance. 

Missed their own QoQ  guidance by 77% and you think their estimated pace of resolution will be true? 
0 chance of that.

$ABR no need for a rate cut tomorrow - that would be institutions creating fear to steal shares.....also grabbed ABR shares today at 4.97 and buying at ~0.4 of book value. ABR mission of  a resolution pace that will resolve nearly all of the delinquencies by year end will clear the air for 2027 but potential for share recovery to commence in advance if they show good progress.

StockTwits Web

Arbor Realty Trust Inc.

Midnight Madness

StockTwits For Android 

 or none of that happens and the NPLs grow in Q2/3/4 and the equity gets wiped out... 

Management has been saying they have "clear path to resolution" for 8 quarters have barely made a dent in the NPL balance. 

Missed their own QoQ  guidance by 77% and you think their estimated pace of resolution will be true? 
0 chance of that.

@ns4 Remeber...one thing. ABR is in the drivers seat and holds the rights contractually on all property in an NPL situation. So you are aware, It takes some time to take over legally depending on the state which slows the process....but the contracts are written in their favor! In some cases several more assets land on their books, rather than flipping, - not ideal for generating earnings but the assets are hard assets and once on ABR books they can be liquidated when they so desire and based on the return they want.  Abr also faced some well capitalized clients..allowing their assets to go to NPL and using this situation to negotiate a better deal....they did negotiate with some....the last batch of npl has forceslosure in flight so borrowers may not want to lose their properties so the chess game continues. With the frivilous lawsuits against ABR dismissed...they have lots more time now to sort this out the rest of the year.

 Remeber...one thing. ABR is in the drivers seat and holds the rights contractually on all property in an NPL situation. So you are aware, It takes some time to take over legally depending on the state which slows the process....but the contracts are written in their favor! In some cases several more assets land on their books, rather than flipping, - not ideal for generating earnings but the assets are hard assets and once on ABR books they can be liquidated when they so desire and based on the return they want.  Abr also faced some well capitalized clients..allowing their assets to go to NPL and using this situation to negotiate a better deal....they did negotiate with some....the last batch of npl has forceslosure in flight so borrowers may not want to lose their properties so the chess game continues. With the frivilous lawsuits against ABR dismissed...they have lots more time now to sort this out the rest of the year.